IDH1 and acute myeloid leukemia: In the setting of newly diagnosed IDH1-mutated AML (76% with secondary AML) patients ineligible for intensive induction therapy, ivosidenib given at dose of 500 mg/daily as single agent demonstrated cCR+CR and CR rates of 42.4% and 30%, respectively, associated with transfusion independence in 42.9%.